MiMedx Group (MDXG) Stock Price
MiMedx Group Price
Over the last 15 years MiMedx Group grew revenue by 51.9% annually, reaching 418.63 M USD. Earnings per share have grown at 17.6% per year over the last 11 years. For MiMedx Group, the net margin of 11.6% is up versus -5.1% a few years ago. The consensus 12-month price target for MiMedx Group is 8.00 USD, about 72.6% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
MiMedx Group stock price
MiMedx Group business model & stock analysis
Frequently asked questions about MiMedx Group
MiMedx Group Inc. operates as a regenerative medicine company, focused on developing and commercializing therapeutic biologics utilizing human placental tissues. The company's business model revolves around the research, development, manufacturing, and distribution of innovative biomaterial solutions for various therapeutic areas. MiMedx Group Inc. harnesses the regenerative properties of human placental tissues to create and provide safe and effective biologic products for wound care, orthopedic, surgical, and sports medicine applications. By leveraging advanced biotechnology, MiMedx aims to improve patient outcomes and enhance the natural healing process. Through its comprehensive and innovative business model, MiMedx Group Inc. strives to make a positive impact in the field of regenerative medicine.
MiMedx Group Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of MiMedx Group Inc in the market include Organogenesis Holdings Inc, Osiris Therapeutics Inc, and Kerecis Limited.
MiMedx Group Inc is a biopharmaceutical company specializing in regenerative medicine. Founded in 2008, MiMedx focuses on developing and commercializing innovative technologies for tissue repair and healing. The company's portfolio includes products derived from human placental tissue, such as AmnioFix and EpiFix, which have shown great potential in treating various chronic and acute wounds. MiMedx Group Inc has made significant strides in the field of regenerative medicine, earning a reputation for its dedication to patient healing and improving quality of life. With a strong focus on research and development, MiMedx remains committed to advancing tissue regeneration and expanding its product offerings.
MiMedx Group Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully received FDA approval for its flagship product, EpiFix, a revolutionary wound healing therapy. This milestone marked a breakthrough in the treatment of chronic wounds and positioned MiMedx as an industry leader. Additionally, MiMedx reached a major milestone when it expanded its product portfolio, launching AmnioFix, a promising regenerative medicine product. The company's commitment to innovation and extensive clinical research has allowed it to achieve remarkable advancements in the field of wound care, enhancing patients' quality of life and solidifying MiMedx's position as an industry frontrunner.
MiMedx Group Inc is primarily present in the United States.
MiMedx Group Inc represents values of innovation, integrity, and patient-centered care. As a leading biopharmaceutical company, MiMedx is dedicated to developing and commercializing regenerative therapies for various medical conditions. Their corporate philosophy revolves around advancing patient outcomes and improving quality of life through their cutting-edge products and solutions. With a focus on research, clinical excellence, and collaboration, MiMedx aims to redefine the standard of care in the industry. By prioritizing patient needs and employing ethical business practices, MiMedx Group Inc reflects their commitment to delivering transformative healthcare solutions.
Analysts currently set an average price target of 8.33 USD for the MiMedx Group stock (median: 8.00 USD), implying +79.7 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the MiMedx Group stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect MiMedx Group to generate revenue of 269.79 M USD and earnings per share of -0.07 USD.
Converted at the current exchange rate, the MiMedx Group share trades at 4.14 EUR (4.64 USD).
The MiMedx Group share (MDXG) is listed on 2 stock exchanges, including: NASDAQ (MDXG), SIX (Zürich) (MXE.SW).
MiMedx Group Inc is a leading provider in the field of tissue regeneration. The company offers various products that contribute to restoring and healing damaged or injured tissue. The company operates in multiple segments and offers its customers a wide range of products and services. The company's main segment is tissue regeneration. Here, MiMedx offers a wide range of products for the treatment of wounds, trauma, burns, and other injuries. Tissue regeneration is an important area of medicine as it can help accelerate the healing of injuries and reduce the risk of complications. Another important segment of the company is biotechnology. MiMedx produces biodegradable materials and biomaterials that can be used for tissue regeneration. Biotechnology is an emerging field in medicine as it reduces the use of synthetic materials and can improve the healing of tissue damage. In the wound care segment, MiMedx offers a wide range of products for the treatment of various types of wounds. This includes ointments, dressings, and special wound dressings that contribute to the support of healing. Another important area is ophthalmology. MiMedx offers products for the treatment of eye diseases. This includes ointments, eye drops, and special contact lenses that contribute to the support of healing. MiMedx's products are used worldwide and utilized by doctors and clinics. The company works closely with medical and research institutions to constantly improve its products and ensure their effectiveness and safety. As a company, MiMedx focuses on innovation and progress. The company is constantly searching for new products and technologies to provide its customers with the best products and services. MiMedx's business model is based on the sale of medical products and services. The company works closely with medical and research institutions to constantly improve its products and ensure their effectiveness and safety. Overall, MiMedx offers its customers a wide range of products and services that can contribute to tissue regeneration and healing of injuries. The company is constantly striving to improve its products and adapt to the needs of its customers. Answer: MiMedx Group Inc is a leading provider in the field of tissue regeneration, offering a wide range of products and services for the restoration and healing of damaged or injured tissue in various medical segments.
The expected revenue of MiMedx Group is 269.79 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of MiMedx Group is -10.48 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of MiMedx Group is currently -66.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MiMedx Group stock.
The price-to-sales ratio (P/S) of MiMedx Group is currently 2.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MiMedx Group stock.
The Eulerpool Quality Score for MiMedx Group is 5/10.
The ISIN of MiMedx Group is US6024961012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of MiMedx Group is A0MS6X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of MiMedx Group is MDXG. The ticker symbol is used to trade MiMedx Group shares on the stock exchange.
MiMedx Group stock
MiMedx Group Peer Group
MiMedx Group Ticker
MiMedx Group FIGI
All fundamentals and in-depth analysis of MiMedx Group
Our stock analysis for MiMedx Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MiMedx Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.